Oct 2026· Genome Research· pp. gr.281596.125· 0 citations
Medicine
TL;DR
Data show that programs such as differentiation regulation, necroptosis, and TGFB topology reshape the selective landscape, constraining the effective potency of driver mutations and explaining why clones differ in their capacity to expand and progress to tumors.
Abstract
Somatic driver mutations pervade phenotypically normal epithelia, yet only a minority of clones progress to tumors. To understand how tissue context modulates clonal selection, we apply the classical two-stage DMBA/TPA model of carcinogenesis to mouse back skin. We collect coordinate-registered, meso-scale grids spanning multiple centimeters with 1-mm punches and profile genotype and transcriptome from the same positions (WES, n = 473; bulk RNA-seq, n = 690), complemented by matched single-cell RNA-seq. This paired, spatially resolved design enables direct coupling of clonal selection metrics to local transcriptional programs. All sequenced papillomas (n = 6) harbor Hras Q61L mutation events, but expected frequency versus observed papillomas indicate that Hras Q61L is necessary but insufficient to drive tumorigenesis within the observation period. To quantify how field-level signaling constrains driver potency, we compute pathway activities and introduce a Laplacian-based "ruggedness" score to capture meso-scale heterogeneity. We find that field-level signaling is rewired before visible tumorigenesis: TNF-associated epithelial necroptosis rises broadly across promoted skin, while TGFB activity becomes spatially "rugged"with papillomas at local TGFB signaling minima. Selection mapping reveals a context shift: in untreated skin, positive selection corresponds with cell cycle deregulation; in the cancerized field, it correlates with impaired differentiation. Moreover, the coupling between WNT signaling and selection evident in untreated tissue is abrogated for DMBA-initiated mutations. These data show that programs such as differentiation regulation, necroptosis, and TGFB topology reshape the selective landscape, constraining the effective potency of driver mutations and explaining why clones differ in their capacity to expand and progress to tumors.
While the genetic paradigm of cancer is powerful, it remains incomplete. For example, high mutational burdens are commonplace in homeostatically-stable epithelia, but the presence of driver mutations alone does not result in cancer. Here, we revealed additional factors contributing to the eco-evolutionary dynamics of c...
S. Avdieiev, L. Tordesillas, Karol Prieto et al.· Cancer Research· 0 citations
Lung adenocarcinoma (LUAD) develops through a defined morphological sequence from atypical adenomatous hyperplasia (AAH) to invasive adenocarcinoma, but the transcriptional programmes accompanying this transition have mostly been characterised in bulk tissue or in tumour tissue alone. We profiled paired samples spannin...
Ewing sarcoma (EwS) is an aggressive FET::ETS fusion-driven pediatric cancer characterized by monomorphous histology and few additional driver mutations, but highly variable outcomes. Here, we analyze EwS and its microenvironment at single-cell and spatial resolution in 135 patients. Our analysis of more than 3 million...
H. Luo, C. Hénon, G. Rukhovich et al.· medRxiv· 0 citations
Whole-genome doubling (WGD) occurs frequently in human cancer and influences tumor evolution, metastasis, and treatment response. Here, we integrate bulk, single-cell, and spatial data to dissect the subclonal dynamics of WGD. Single-cell data analysis shows that WGD cells are prevalent even in tumors that are classifi...
Fu-Nan He, M. Noureen, E. Dray et al.· Science Advances· 0 citations
Cell competition is a conserved fitness-surveillance process, first described in Drosophila epithelia, by which cells compare relative fitness with their neighbors so that less-fit “loser” cells are eliminated, extruded or forced to differentiate while fitter “winner” cells expand. In the tumor microenvironment (TME),...
P. Balu, A. Sureshkumar, Gayathri Devi Sundaramurthy et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.